CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"
The company's Founder and Executive Chairman, Dr. Chad Gordon, is a leader in Neuroplastic and Reconstructive Surgery. He serves as Section Chief and Fellowship Program Director at Johns Hopkins School of Medicine. Over his career, Dr. Gordon has secured 21 patents, led three successful venture exits, and conducted three first-in-human studies evaluating advanced cranial implants. His invention of the NeuroPASS™ device—CraniUS's core innovation—sparked the company's formation.
This award acknowledges CraniUS's leadership and its groundbreaking development of the NeuroPASS™ platform, which enables direct, reliable delivery of therapeutics to the brain—addressing one of the most persistent challenges in treating brain tumors and other neurological conditions.
"We are honored to be recognized by the Maryland Tech Council with this year's Emerging Company Award," said Dr. Gordon. "This milestone reflects not only the dedication of our entire team but also the urgent need for transformative solutions in neurotherapeutics. We are extremely proud to be pioneering the new field of functional neurocranial implants inspired by Neuroplastic Surgery and driving this critical work forward—from right here in Maryland."
Mike Maglin, CEO of CraniUS Therapeutics, added, "This award is a testament to the meaningful progress we've made and the momentum we've built—spanning scientific innovation, strategic alliances, and investor engagement. We remain committed to redefining how patients with neurological diseases receive life-changing medicines."
The Industry Awards Celebration is Maryland's premier event honoring excellence in technology, life sciences, and innovation. CraniUS was selected from a competitive field of nominees for its rapid growth, strong leadership, and the promise of its revolutionary device platform—employing patented neurotechnology—designed to reshape treatment approaches for conditions such as neurodegenerative diseases, movement disorders, and aggressive brain cancers.
About CraniUS TherapeuticsCraniUS Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types. CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing.
Media Contact:Elizabeth A. Dale, EdDExecutive Advisor, CraniUS Therapeuticsedale@craniusmed.com215-620-4482
View original content to download multimedia:https://www.prnewswire.com/news-releases/cranius-therapeutics-awarded-maryland-tech-councils-2025-emerging-life-sciences-company-of-the-year-302467613.html
SOURCE CraniUS Therapeutics
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
BofA names Faiz Ahmad, Mike Joo as new co-heads of investment banking, memo says
NEW YORK (Reuters) -Bank of America on Wednesday announced a reshuffle in its global corporate and investment banking (GCIB) business, naming Faiz Ahmad and Mike Joo as new co-heads of global investment banking, according to an internal memo seen by Reuters. The current heads of investment banking, Alex Bettamio and Thomas Sheehan, will become chairs of GCIB, tasked with deepening client relationships globally, according to the memo by Matthew Koder, president of BofA's GCIB. Bank of America is the third-largest bank in 2025 by global investment banking revenue, according to Dealogic as of mid-August. It has 6% market share, slightly lower than its 6.1% last year. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
First Horizon Corporation to Participate in the Barclays 23rd Annual Global Financial Services Conference
MEMPHIS, Tenn., Aug. 20, 2025 /PRNewswire/ -- First Horizon Corporation (NYSE: FHN) today announced Chairman of the Board, President, and Chief Executive Officer Bryan Jordan and Chief Financial Officer Hope Dmuchowski will participate in the Barclays 23rd Annual Global Financial Services Conference on September 9, 2025, at 12:00 pm ET. A live webcast of the event along with an audio replay will be available via the events and presentations section of the First Horizon Investor Relations website at The presentation and any related materials may contain forward-looking statements, including guidance, involving significant risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements, including those factors described in FHN's recent 10-K, 10-Q, 8-K, and other reports and filings with the SEC. FHN disclaims any obligation to update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements to reflect future events or developments. About First Horizon First Horizon Corporation (NYSE: FHN), with $82.1 billion in assets as of June 30, 2025, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at View original content to download multimedia: SOURCE First Horizon Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Angelalign Technology Denies Patent Infringement and Vows Vigorous Defense
SAN CLEMENTE, Calif., Aug. 21, 2025 /PRNewswire/ -- Angelalign Technology Inc. ( ("Angel") categorically denies accusations of patent infringement by Align Technology Inc. (ALGN) and promises a vigorous defense. "Angel has a rich heritage of clinically driven innovation during its 20-plus year history. Accusations by our competitor of patent violations are frivolous and entirely without merit," said Angel's Chief Commercial Officer and SVP, Rich Hirschland. "Angel has invested heavily in patent compliance since our founding. We are confident that we will prevail in this case." Angel has proudly led the clear-aligner field in innovation for many years. Among its cutting-edge products are the award-winning angelButton™, the angelHook, the A6 mandibular advancement system (now celebrating its ten-year anniversary), the angelKid system, and the Intelligent Root System. The company is committed to bringing fair and healthy competition to the marketplace to benefit doctors and their patients. Angel's products regularly receive high doctor-satisfaction scores. Its flexible manufacturing system also has been widely praised for turning complex clinical ideas into workable solutions. These innovations, powered by a corporate culture that focuses on treating employees and customers well, have led to impressive global growth for Angel, which is expected to continue. "We anticipate that our growth will not be materially affected by the lawsuits," Hirschland said. "We look forward to using the lawsuits to tell the Angel success story and help attract more customers to Angel around the world." About Angelalign Technology in 2003 and celebrating 1.5 million smiles, Angelalign Technology Inc. provides digital technology-driven clear aligner products and services to meet the needs of dental professionals and patients worldwide. The Company's innovative products and technical services have established it as a prominent player in the orthodontics industry. In 2021, Angelalign Technology was listed on the Hong Kong Stock Exchange. In 2023, the Company launched its global expansion strategy, with its products and services now reaching over 50 countries and regions. Learn more at Media Contact:Sue View original content: SOURCE Angel Aligner
